Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results Enrollment Completed for Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss; Readout ...

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that ...

There have been many FCC spectrum auctions over the last couple of years to aid in 5G network development, but none with as much lasting impact on the ecosystem as C-band. At the major auction last ...

FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023 Reports Cash and Cash Equivalents of $124.8M, Providing Runway ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate ...